Guidelines for interactions between clinical faculty and the pharmaceutical industry: One medical school's approach

Academic Medicine

Volumn 81, Issue 2, 2006, Pages 154-160

  Coleman, David L ^a   Kazdin, Alan E ^b   Miller, Lee Ann ^c   Morrow, Jon S ^a   Udelsman, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED STUDY; DRUG INDUSTRY; HUMAN; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL SCHOOL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES; ARTICLE; CONFLICT OF INTEREST; COOPERATION; ETHICS; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; ORGANIZATION AND MANAGEMENT; POLICY; RESEARCH ETHICS; STANDARD;

CODES OF ETHICS; CONFLICT OF INTEREST; CONNECTICUT; COOPERATIVE BEHAVIOR; DISCLOSURE; DRUG INDUSTRY; ETHICS, RESEARCH; FACULTY, MEDICAL; GUIDELINES; HUMANS; ORGANIZATIONAL POLICY; SCHOOLS, MEDICAL; UNITED STATES;

EID: 33645804026     PISSN: 10402446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001888-200602000-00011     Document Type: Review

References (27)

1. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry: self-regulation in the shadow of federal prosecution. N Engl J Med 2004;351:1891- 900.
2. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885-90.
3. Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2004. Washington, DC: PhRMA, 2004.
4. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ. 2003;326:1189-96.
5. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-80.
6. Furguson RP, Rhim E, Belizaire W, Egede L, Carter K, Lansdale T. Encounters with pharmaceutical sales representatives among practicing internists. Am J Med. 1999;107:149-52.
7. National survey of physicians. Part 2. Doctors and prescription drugs 〈http://www.kff.org/rxdrugs/20020415b-index.cfm〉. Accessed 27 October 2005. Kaiser Family Foundation, Washington, DC, March 2002.
8. Keim SM, Mays MZ, Grant D. Interactions between emergency medicine programs and the pharmaceutical industry. Acad Emerg Med. 2004;11:19-26.
9. ACCME annual report data 2004 〈http:// www.accme.org/dir_docs/ doc_upload/2130a818-1c9f-400b-9d54-56b3f8f9a2f6_uploaddocument.pdf〉. Accessed 27 October 2005. Accreditation Council for Continuing Medical Education, Chicago 2004.
10. McKinney W, Schiedermayer D, Lurie N, Simpson D, Goodman J, Rich E. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA. 1990;264:1693-97.
11. Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF. The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Pract. 2000;49:817-19.
12. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551-57.
13. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252-55.
14. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med. 2003;163:2213-18.
15. Scherer FM. The pharmaceutical industry: prices and progress. N Engl J Med. 2004;351:927-32.
16. Eaton L. Readers want transparency in link between doctors and drug firms. BMJ. 2003;326:1352.
17. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101-6.
18. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287:612-17.
19. American Medical Association. Opinion of the Council on Ethical and Judicial Affairs, E-8.061 〈http://www.ama-assn.org/ama/pub/category/4001. html〉. Accessed 25 October 2005.
20. Coyle SL. Physician industry relations. Part 1: Individual physicians. Ann Intern Med. 2002;136:396-402.
21. Coyle SL. Physician-industry relations. Part 2: Organizational issues. Ann Intern Med. 2002;136:403-6.
22. Department of Health and Human Services, Office of Inspector General. OIG compliance program guidance for pharmaceutical manufacturers. Fed Regist. 2003;68:23731-43.
23. Pharmaceutical Research and Manufacturers of America. PhRMA code on interactions with healthcare professionals. Washington, DC: PhRMA, 2002.
24. Accreditation Council for Continuing Medical Education Report on Standards for Commercial Support 〈http://www.accme.org/dir_docs/doc_upload/ 68b2902a-fb73-44d1-8725-80a1504e520c_uploaddocument.pdf〉. Accessed 25 October 2005.
25. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical gift giving. Am J Bioeth. 2003;3:39-46.
26. Westfall JM, McCabe J, Nicholas RA. Personal use of drug samples by physicians and office staff. JAMA. 1997;278:141-43.
27. Ask ACME. Standards for Commercial Support, 2: Resolution of Personal Conflicts of Interest 〈http://www.accme.org/index.cfm/fa/faq.detail/ category_id/6a4a0ce7-1e62-4fc9-a437-1e6e7eedecb2.cfm〉. Accessed 25 October 2005.